Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinal Diseases | 4 | 2005 | 172 | 0.420 |
Why?
|
| Fluorescein Angiography | 4 | 2019 | 139 | 0.280 |
Why?
|
| Eye Infections, Bacterial | 2 | 2000 | 90 | 0.270 |
Why?
|
| Fundus Oculi | 5 | 2019 | 63 | 0.260 |
Why?
|
| Laser Coagulation | 2 | 2005 | 129 | 0.260 |
Why?
|
| Visual Acuity | 5 | 2019 | 808 | 0.240 |
Why?
|
| Retinal Vessels | 1 | 2005 | 73 | 0.230 |
Why?
|
| Endophthalmitis | 2 | 2004 | 76 | 0.220 |
Why?
|
| Retinal Detachment | 3 | 2019 | 83 | 0.200 |
Why?
|
| Actinomycetales | 1 | 2000 | 3 | 0.170 |
Why?
|
| Actinomycetales Infections | 1 | 2000 | 12 | 0.170 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2000 | 19 | 0.170 |
Why?
|
| Eye Foreign Bodies | 1 | 2000 | 15 | 0.170 |
Why?
|
| Retinal Perforations | 1 | 2019 | 27 | 0.170 |
Why?
|
| Wound Infection | 1 | 2000 | 51 | 0.160 |
Why?
|
| Retinopathy of Prematurity | 1 | 2019 | 56 | 0.160 |
Why?
|
| Endocarditis, Bacterial | 2 | 2004 | 129 | 0.160 |
Why?
|
| Polymethyl Methacrylate | 1 | 1998 | 24 | 0.150 |
Why?
|
| Silicone Oils | 1 | 1998 | 11 | 0.150 |
Why?
|
| Acrylic Resins | 1 | 1998 | 25 | 0.150 |
Why?
|
| Humidity | 1 | 1998 | 23 | 0.150 |
Why?
|
| Silicone Elastomers | 1 | 1998 | 35 | 0.150 |
Why?
|
| Astrocytoma | 1 | 1999 | 103 | 0.150 |
Why?
|
| Retinal Neoplasms | 1 | 1999 | 98 | 0.140 |
Why?
|
| Vitreous Body | 3 | 2000 | 105 | 0.140 |
Why?
|
| Choroid Hemorrhage | 1 | 1996 | 1 | 0.130 |
Why?
|
| Plasminogen Activators | 1 | 1996 | 20 | 0.130 |
Why?
|
| Retina | 1 | 2019 | 455 | 0.130 |
Why?
|
| Bone Marrow Transplantation | 2 | 1996 | 577 | 0.130 |
Why?
|
| Nevus of Ota | 1 | 1995 | 2 | 0.130 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 1996 | 83 | 0.120 |
Why?
|
| Glaucoma, Open-Angle | 1 | 1995 | 38 | 0.120 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1996 | 111 | 0.120 |
Why?
|
| Ophthalmology | 1 | 1998 | 197 | 0.120 |
Why?
|
| Choroid Neoplasms | 1 | 1994 | 25 | 0.120 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 1994 | 14 | 0.120 |
Why?
|
| Optic Nerve Diseases | 1 | 1996 | 88 | 0.120 |
Why?
|
| Retinal Hemorrhage | 1 | 1994 | 22 | 0.110 |
Why?
|
| Vitrectomy | 3 | 2000 | 108 | 0.110 |
Why?
|
| Lenses, Intraocular | 1 | 1998 | 395 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 1996 | 1232 | 0.100 |
Why?
|
| Blood | 2 | 2005 | 105 | 0.100 |
Why?
|
| Daunorubicin | 1 | 1991 | 27 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1994 | 654 | 0.080 |
Why?
|
| Staphylococcal Infections | 1 | 1994 | 553 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 1995 | 798 | 0.080 |
Why?
|
| Rabbits | 4 | 1998 | 709 | 0.070 |
Why?
|
| Breast Neoplasms | 2 | 1996 | 2478 | 0.070 |
Why?
|
| Choroid Diseases | 2 | 1996 | 21 | 0.060 |
Why?
|
| Capillary Permeability | 1 | 2005 | 77 | 0.060 |
Why?
|
| Intraocular Pressure | 2 | 1995 | 144 | 0.060 |
Why?
|
| Injections | 2 | 2000 | 153 | 0.050 |
Why?
|
| Fluorouracil | 2 | 1998 | 129 | 0.040 |
Why?
|
| Ultrasonography | 2 | 1996 | 942 | 0.040 |
Why?
|
| Male | 8 | 2019 | 60334 | 0.040 |
Why?
|
| Adult | 4 | 2019 | 29100 | 0.040 |
Why?
|
| Metals | 1 | 2000 | 62 | 0.040 |
Why?
|
| Humans | 11 | 2019 | 123262 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2000 | 1142 | 0.040 |
Why?
|
| Epiretinal Membrane | 1 | 1999 | 15 | 0.040 |
Why?
|
| Choroidal Neovascularization | 1 | 1999 | 29 | 0.040 |
Why?
|
| Capsulorhexis | 1 | 1998 | 17 | 0.040 |
Why?
|
| Hyperplasia | 1 | 1999 | 209 | 0.040 |
Why?
|
| Durapatite | 1 | 1998 | 17 | 0.040 |
Why?
|
| Vitreoretinopathy, Proliferative | 1 | 1998 | 6 | 0.040 |
Why?
|
| Triamcinolone | 1 | 1998 | 14 | 0.040 |
Why?
|
| Cisplatin | 2 | 1996 | 242 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 1998 | 5056 | 0.040 |
Why?
|
| Middle Aged | 5 | 2019 | 26091 | 0.040 |
Why?
|
| Gentamicins | 1 | 1998 | 95 | 0.040 |
Why?
|
| Intraoperative Complications | 1 | 1998 | 174 | 0.030 |
Why?
|
| Cyclophosphamide | 2 | 1996 | 422 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 1998 | 150 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 1998 | 208 | 0.030 |
Why?
|
| Aged | 3 | 2019 | 19198 | 0.030 |
Why?
|
| Demyelinating Diseases | 1 | 1996 | 67 | 0.030 |
Why?
|
| Carmustine | 1 | 1996 | 26 | 0.030 |
Why?
|
| History, 20th Century | 1 | 1998 | 381 | 0.030 |
Why?
|
| Choroid | 1 | 1996 | 39 | 0.030 |
Why?
|
| Timolol | 1 | 1995 | 8 | 0.030 |
Why?
|
| Reoperation | 1 | 1999 | 819 | 0.030 |
Why?
|
| Anterior Eye Segment | 1 | 1995 | 30 | 0.030 |
Why?
|
| Ophthalmic Solutions | 1 | 1995 | 89 | 0.030 |
Why?
|
| Sclera | 1 | 1995 | 58 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 1998 | 456 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 1996 | 297 | 0.030 |
Why?
|
| Optic Disk | 1 | 1995 | 44 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 1998 | 378 | 0.030 |
Why?
|
| Optic Nerve | 1 | 1996 | 116 | 0.030 |
Why?
|
| Lens Implantation, Intraocular | 1 | 1998 | 342 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 1998 | 644 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 2030 | 0.030 |
Why?
|
| Ischemia | 1 | 1996 | 344 | 0.030 |
Why?
|
| Disease Models, Animal | 3 | 1998 | 4298 | 0.030 |
Why?
|
| Female | 6 | 2019 | 65618 | 0.020 |
Why?
|
| Adolescent | 3 | 2019 | 19127 | 0.020 |
Why?
|
| Random Allocation | 1 | 1991 | 433 | 0.020 |
Why?
|
| Eye Diseases | 1 | 1991 | 113 | 0.020 |
Why?
|
| Fibroblasts | 2 | 1991 | 884 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 6223 | 0.020 |
Why?
|
| Cell Division | 1 | 1991 | 783 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 1991 | 726 | 0.020 |
Why?
|
| Animals | 5 | 1998 | 33852 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 1996 | 1003 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2000 | 2398 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 1996 | 1201 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 8867 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 1994 | 1591 | 0.010 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2004 | 133 | 0.010 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2004 | 238 | 0.010 |
Why?
|
| Abscess | 1 | 2004 | 138 | 0.010 |
Why?
|
| Heart Valve Diseases | 1 | 2004 | 166 | 0.010 |
Why?
|
| United States | 1 | 1998 | 10654 | 0.010 |
Why?
|
| Aortic Diseases | 1 | 2004 | 198 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2019 | 16069 | 0.010 |
Why?
|
| Aortic Valve Stenosis | 1 | 2004 | 332 | 0.010 |
Why?
|
| Child | 1 | 2019 | 24256 | 0.010 |
Why?
|
| Osseointegration | 1 | 1998 | 8 | 0.010 |
Why?
|
| Drug Implants | 1 | 1998 | 42 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1998 | 95 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 1998 | 110 | 0.010 |
Why?
|
| Electroretinography | 1 | 1998 | 114 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 1998 | 123 | 0.010 |
Why?
|
| Orbit | 1 | 1998 | 102 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1998 | 339 | 0.010 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1996 | 3 | 0.010 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1996 | 16 | 0.010 |
Why?
|
| Scotoma | 1 | 1996 | 16 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1996 | 355 | 0.010 |
Why?
|
| Visual Fields | 1 | 1996 | 133 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1996 | 300 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 1996 | 323 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 1385 | 0.010 |
Why?
|
| Methotrexate | 1 | 1996 | 343 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 1996 | 231 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1998 | 1389 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1996 | 1239 | 0.010 |
Why?
|
| Rose Bengal | 1 | 1991 | 14 | 0.010 |
Why?
|
| Cats | 1 | 1991 | 116 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1996 | 1878 | 0.010 |
Why?
|
| Light | 1 | 1991 | 175 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1998 | 3020 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 1991 | 2844 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 1998 | 12170 | 0.000 |
Why?
|